NeoGenomics, Inc.
$8.90+6.08%(+$0.51)
TickerSpark Score
59/100
80
Valuation
35
Profitability
45
Growth
84
Health
50
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEO research report →
52-Week Range46% of range
Low $4.72
Current $8.90
High $13.74
Companywww.neogenomics.com
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments.
- CEO
- Anthony Zook
- IPO
- 2004
- Employees
- 2,200
- HQ
- Fort Myers, FL, US
Price Chart
+11.39% · this period
Valuation
- Market Cap
- $231.78M
- P/E
- -2.32
- P/S
- 0.31
- P/B
- 0.28
- EV/EBITDA
- -15.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 42.13%
- Op Margin
- -13.94%
- Net Margin
- -13.30%
- ROE
- -11.82%
- ROIC
- -7.97%
Growth & Income
- Revenue
- $727.33M · 10.11%
- Net Income
- $-108,025,000 · -37.22%
- EPS
- $-4.20 · -35.48%
- Op Income
- $-66,078,999
- FCF YoY
- 36.02%
Performance & Tape
- 52W High
- $13.74
- 52W Low
- $4.72
- 50D MA
- $8.28
- 200D MA
- $9.58
- Beta
- 1.80
- Avg Volume
- 1.98M
Get TickerSpark's AI analysis on NEO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Olivo Alicia C | other | 3,944 |
| May 11, 26 | Olivo Alicia C | other | 2,559 |
| May 11, 26 | Olivo Alicia C | other | 3,944 |
| May 11, 26 | Stone Warren | other | 5,830 |
| May 11, 26 | Stone Warren | other | 3,783 |
| May 11, 26 | Stone Warren | other | 5,830 |
| May 2, 26 | Aunan Greg D | other | 5,372 |
| May 2, 26 | Aunan Greg D | other | 1,309 |
| May 1, 26 | Aunan Greg D | other | 937 |
| May 2, 26 | Aunan Greg D | other | 5,372 |
Our NEO Coverage
We haven't published any research on NEO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NEO Report →